This website uses cookies for a range of purposes to help us understand your interests and improve the website. By using our website, you acknowledge the use of essential cookies and consent to the use of non-essential cookies, as described in our Cookie Policy. To understand more about how we use cookies or to change your preference and browser settings, please see our Cookie policy

Back toDeals, Cases & Projects
Advanced
Filters

IMV completes registered direct offering for proceeds of approximately US$9M

Date Closed

December 20, 2022

Lead Office

Québec City

Value

9.00 Million USD

On December 20, 2022, IMV Inc. closed its previously announced registered direct offering for total gross proceed of approximately US$9M. 

IMV intends to use the net proceeds from the offering to continue the clinical development of its lead product candidate, maveropepimut-S, in diffuse large B cell lymphoma (DLBCL), ovarian cancer, the completion of its ongoing basket trial and to continue the development of its proprietary drug delivery platform (DPX®) and for general corporate purposes. 

IMV Inc. is a clinical-stage immuno-oncology company advancing a portfolio of therapies based on the Company’s immune-educating platform, DPX®

McCarthy Tétrault LLP advised IMV with a team led by Philippe Leclerc that included Mireille Trottier, Annie Poirier-Simard (Securities), Marie-Soleil Landry and Geneviève Favreau (Tax).

People